natgillin/translations-raw huggingface dataset:
The most common adverse reactions (occurring in > 20% of subjects) were: anaemia, fatigue, diarrhoea, thrombocytopenia, nausea, pyrexia, dyspnoea, respiratory tract infection, cough and peripheral oedema.
Najčešće nuspojave (javljaju se u > 20% ispitanika) bile su: anemija, umor, proljev, trombocitopenija, mučnina, pireksija, dispneja, infekcije dišnog sustava, kašalj i periferni edem.
The most common adverse reactions (≥ 20 %) for trametinib and dabrafenib combination therapy include pyrexia, fatigue, nausea, headache, chills, diarrhoea, rash, arthralgia, hypertension, vomiting and cough.
Najčešće nuspojave (≥ 20%) kombinirane terapije trametinibom i dabrafenibom uključuju pireksiju, umor, mučninu, glavobolju, zimicu, proljev, osip, artralgiju, hipertenziju, povraćanje i kašalj.
The most common adverse reactions (≥ 3% in pooled Phase 3 trials) occurring in patients receiving Zerbaxa were nausea, headache, constipation, diarrhoea, and pyrexia and were generally mild or moderate in severity.
Najčešće nuspojave (≥3% u objedinjenim ispitivanjima faze 3) u bolesnika koji su primali lijek Zerbaxa bile su mučnina, glavobolja, konstipacija, dijareja i vrućica te su općenito bile blage ili umjereno teške.
The most common adverse reactions (≥ 5 % and at least twice the rate of placebo) reported in paediatric patients with bipolar I disorder were somnolence, sedation, dizziness, dysgeusia, hypoaesthesia oral, paraesthesia oral, nausea, increased appetite, fatigue, and weight increased (see Weight increase above).
Najčešće nuspojave (≥ 5% i najmanje dvostruko u odnosu na placebo) prijavljene u pedijatrijskih bolesnika s bipolarnim poremećajem tipa I bile su somnolencija, sedacija, omaglica, disgeuzija, oralna hipoestezija, oralna parestezija, mučnina, pojačan tek, umor i porast tjelesne težine (vidjeti Porast tjelesne težine gore).
The most common adverse reactions (≥20%) for trametinib include rash, diarrhoea, fatigue, oedema peripheral, nausea, and dermatitis acneiform.
Najčešće nuspojave kod primjene trametiniba (≥ 20%) uključuju osip, proljev, umor, periferni edem, mučninu i akneiformni dermatitis.
The most common adverse reactions (20%) for dabrafenib and trametinib combination therapy include pyrexia, fatigue, nausea, headache, chills, diarrhoea, rash, arthralgia, hypertension, vomiting and cough.
Najčešće nuspojave (≥ 20%) kombinirane terapije dabrafenibom i trametinibom uključuju pireksiju, umor, mučninu, glavobolju, zimicu, proljev, osip, artralgiju, hipertenziju, povraćanje i kašalj.
The most common adverse reactions are asthenia/fatigue, hot flush, headache, and hypertension.
Najčešće nuspojave su astenija/umor, navale vrućine, glavobolja i hipertenzija.
The most common adverse reactions are pharmacologically predictable adverse reactions of β2 adrenoceptor agonist therapy, such as tremor and palpitations.
Najčešće nuspojave su farmakološki predvidive nuspojave terapije ß 2- adrenoreceptorskim agonistima, kao što su tremor i palpitacije.
The most common adverse reactions are pharmacologically predictable adverse reactions of β2 adrenoceptor agonist therapy, such as tremor and palpitations.
Najčešće nuspojave su farmakološki predvidive nuspojave terapije ß 2-adrenoreceptorskim agonistima, kao što su tremor i palpitacije.
The most common adverse reactions are pharmacologically predictable adverse reactions of β2 adrenoceptor agonist therapy, such as tremor and palpitations.
Najčešće nuspojave su farmakološki predvidive nuspojave terapije ß2- adrenoreceptorskim agonistima, kao što su tremor i palpitacije.
The most common adverse reactions for Dynastat is nausea.
Najčešća nuspojava Dynastata je mučnina.
The most common adverse reactions in paediatric ITP patients 1 year and older (≥ 3% and greater than placebo) were upper respiratory tract infection, nasopharyngitis, cough, diarrhoea, pyrexia, rhinitis, abdominal pain, oropharyngeal pain, toothache, rash, increased AST and rhinorrhoea.
Najčešće nuspojave u pedijatrijskih bolesnika s ITP-om u dobi od 1 i više godina (≥ 3% i više od placeba) bile su infekcija gornjeg dijela dišnog sustava, nazofaringitis, kašalj, proljev, pireksija, rinitis, bol u abdomenu, orofaringealna bol, zubobolja, osip, povišeni AST i rinoreja.
The most common adverse reactions in pivotal study PA.3 in pancreatic cancer patients receiving Tarceva 100 mg plus gemcitabine were fatigue, rash and diarrhoea.
Najčešće nuspojave u središnjem ispitivanju PA.3 u bolesnika s rakom gušterače koji su primali lijek Tarceva 100 mg u kombinaciji s gemcitabinom bile su umor, osip i proljev.
The most common adverse reactions leading to discontinuation during the first 16 weeks of treatment were diarrhoea (1.7%), and nausea (1.5%).
Najčešće nuspojave koje su dovele do prekida terapije u prvih 16 tjedana liječenja bile su proljev (1,7%) i mučnina (1,5%).
The most common adverse reactions observed in clinical studies conducted with the Pandemic influenza vaccine H5N1 MedImmune in healthy adults was headache (25.4%) and upper respiratory infection (10.2%).
Najčešće nuspojave zamijećene u kliničkim ispitivanjima provedenima s Pandemijskim cjepivom protiv influence H5N1 MedImmune u zdravih ispitanika bile su glavobolja (25,4%) i infekcije gornjih dišnih puteva (10,2%).
The most common adverse reactions observed in ramucirumab-treated patients are: neutropenia, fatigue/asthenia, leukopenia, epistaxis, diarrhoea and stomatitis.
Najčešće nuspojave primijećene u bolesnika liječenih ramucirumabom su: neutropenija, umor/astenija, leukopenija, epistaksa, proljev i stomatitis.
The most common adverse reactions occurring in at least 10% of patients included: headache, anaemia, decreased appetite, insomnia, cough, nausea, diarrhoea, alopecia, pruritus, myalgia, pyrexia, fatigue, influenza- like illness, asthenia, chills and peripheral oedema.
Najčešće nuspojave koje su se pojavile u najmanje 10% bolesnika uključivale su: glavobolju, anemiju, smanjeni apetit, nesanicu, kašalj, mučninu, proljev, alopeciju, svrbež, mialgiju, pireksiju, umor, bolest sličnu gripi, asteniju, zimicu i periferne edeme.
The most common adverse reactions occurring in at least 10% of patients included: headache, anaemia, decreased appetite, insomnia, cough, nausea, diarrhoea, alopecia, pruritus, myalgia, pyrexia, fatigue, influenza-like illness, asthenia, chills and peripheral oedema.
Najčešće nuspojave koje su se pojavile u najmanje 10% bolesnika uključivale su: glavobolju, anemiju, smanjeni apetit, nesanicu, kašalj, mučninu, proljev, alopeciju, svrbež, mialgiju, pireksiju, umor, bolest sličnu gripi, asteniju, zimicu i periferne edeme.
The most common adverse reactions occurring in at least 10% of patients included: headache, dizziness, insomnia, cough, dyspnoea, oropharyngeal pain, rhinorrhoea, nausea, diarrhoea, abdominal pain, transaminases increased, ecchymosis, arthralgia, muscle spasms, pain in extremity, fatigue, febrile neutropenia, and pyrexia.
Najčešće nuspojave koje su se pojavile u najmanje 10% bolesnika uključivale su: glavobolju, omaglicu, nesanicu, kašalj, dispneju, orofaringealnu bol, rinoreju, mučninu, proljev, bol u abdomenu, porast transaminaza, ekhimozu, artralgiju, spazme mišića, bol u ekstremitetima, umor, febrilnu neutropeniju, i pireksiju.
The most common adverse reactions occurring in ≥ 1 % of patients treated with dalbavancin were nausea (2.4 %), diarrhoea (1.9 %), and headache (1.3 %) and were generally of mild or moderate severity.
Najčešće nuspojave koje su se pojavile kod ≥ 1 % bolesnika liječenih dalbavancinom bile su mučnina (2,4 %), proljev (1,9 %) i glavobolja (1,3 %), te su uglavnom bile blage ili umjerene težine.
The most common adverse reactions occurring in ≥ 3% of patients treated with Zinforo were diarrhoea, headache, nausea, and pruritus, and were generally mild or moderate in severity.
Najčešće nuspojave koje su se javile u ≥ 3% bolesnika liječenih lijekom Zinforo bile su proljev, glavobolja, mučnina i svrbež, a uglavnom su bile blagog ili umjerenog intenziteta.
The most common adverse reactions occurring in ≥ 3% of patients treated with Zinforo were nausea, headache, and rash.
Najčešće nuspojave koje su se javljale u ≥ 3% bolesnika liječenih lijekom Zinforo bile su mučnina, glavobolja i osip.
The most common adverse reactions of any grade (experienced by patients in RCC, GIST, and pNET registrational trials) included decreased appetite, taste disturbance, hypertension, fatigue, gastrointestinal disorders (i.e. diarrhoea, nausea, stomatitis, dyspepsia and vomiting), skin discolouration, and palmar-plantar erythrodysaesthesia syndrome.
Najčešći štetni događaji bilo kojeg stupnja (koji su nastupili u bolesnika u registracijskim ispitivanjima u indikacijama RCC, GIST i pNET) uključivali su: slabiji tek, poremećaj okusa, hipertenziju, umor, poremećaje probavnog sustava (tj. proljev, mučninu, stomatitis, dispepsiju i povraćanje), promjene boje kože i sindrom palmarno-plantarne eritrodizestezije.
The most common adverse reactions of any severity grade were neutropenia, nausea, vomiting, increase in AST/ALT, anaemia, fatigue, thrombocytopenia, anorexia and diarrhoea.
Najčešće nuspojave bilo kojeg stupnja težine bile su neutropenija, mučnina, povraćanje, porast razina AST- a/ALT-a, anemija, umor, trombocitopenija, anoreksija i proljev.
The most common adverse reactions related to Kaletra therapy during clinical trials were diarrhoea, nausea, vomiting, hypertriglyceridaemia and hypercholesterolemia.
Najčešće nuspojave pri uzimanju lijeka Kaletra u kliničkim ispitivanjima bile su proljev, mučnina, povraćanje, hipertrigliceridemija i hiperkolesterolemija.
The most common adverse reactions reported at a greater incidence in adults treated with the aprepitant regimen than with standard therapy in patients receiving Highly Emetogenic Chemotherapy (HEC) were: hiccups (4.6 % versus 2.9 %), alanine aminotransferase (ALT) increased (2.8 % versus
Najčešće nuspojave prijavljene s većom incidencijom u odraslih liječenih aprepitantom nego standardnom terapijom među bolesnicima koji su primali jako emetogenu kemoterapiju (engl.
The most common adverse reactions reported for patients treated with Betmiga 50 mg during the three 12-week phase 3 double blind, placebo controlled studies are tachycardia and urinary tract infections.
Najčešće nuspojave prijavljene su kod bolesnika koji su liječeni s 50 mg lijeka Betmiga tijekom 3 dvostruko slijepa, placebo kontrolirana ispitivanja faze 3, u trajanju od 12 tjedana, bile su tahikardija i infekcije urinarnog trakta.
The most common adverse reactions reported in conjunction with overdose in these cases included bradycardia, hypotension, oversedation, somnolence and cardiac arrest.
Najčešće zabilježene nuspojave povezane s predoziranjem u tim su slučajevima uključivale bradikardiju, hipotenziju, prejaku sedaciju, pospanost i srčani zastoj.
The most common adverse reactions reported were malaise and fatigue, respiratory tract infections, throat and tonsil discomfort, headache, abdominal discomfort and pain, nausea, vomiting and diarrhoea.
Najčešće zabilježene nuspojave bile su opća slabost i umor, infekcije dišnih puteva, nelagoda u predjelu grla i krajnika, glavobolja, bol i nelagoda u trbuhu, mučnina, povraćanje i proljev.
The most common adverse reactions resulting in discontinuation from the rufinamide treatment group were rash and vomiting.
Najčešće nuspojave koje su rezultirale prekidom u skupini liječenoj rufinamidom bile su osip i povraćanje.
The most common adverse reactions resulting in discontinuation from the Rufinamide treatment group were rash and vomiting.
Najčešće nuspojave, koje su rezultirale prekidom u skupini liječenoj rufinamidom bile su osip i povraćanje.
The most common adverse reactions resulting in discontinuation from the rufinamide treatment group were rash and vomiting.
Najčešće nuspojave, koje su rezultirale prekidom u skupini liječenoj rufinamidom, bile su osip i povraćanje.
The most common adverse reactions seen are peripheral oedema, hypokalaemia, hypertension and urinary tract infection.
Najčešće opažene nuspojave su periferni edem, hipokalemija, hipertenzija i infekcija mokraćnih puteva.
The most common adverse reactions were eye pain (19.2%), eye irritation (17.8%), lacrimation (6. 4%), ocular hyperaemia (5.5%) and eyelid erythema (1.7%) which were usually transitory and occurred during instillation.
Najčešće nuspojave bile su bol u oku (19,2%), iritacija oka (17,8%), suzenje (6,4%), hiperemija očiju (5,5%) te eritem vjeđe (1,7%); obično su bile prolazne i javljale se tijekom ukapavanja.
The most common adverse reactions were gastrointestinal effects.
Najčešće nuspojave bili su vezane uz učinak lijeka na gastrointestinalni sustav.
The most common adverse reactions were headache, nasopharyngitis, back pain, and arthralgia , which were common, by MedDRA definition, in both the Circadin and placebo treated groups.
Najčešće nuspojave bile su glavobolja, nazofaringitis, bol u leđima i artralgija, koje su prema MedDRA definiciji bile česte, kako u skupini koja je uzimala Circadin, tako i u skupini koja je uzimala placebo.
The most common adverse reactions were nausea and dizziness.
Najčešće nuspojave bile su mučnina i omaglica.
The most common adverse reactions were peripheral oedema and dizziness, see also section 4.8. The adverse reactions reported were in agreement with those anticipated from the safety profiles of the components telmisartan and amlodipine.
Najčešće nuspojave bile su periferni edem i omaglica, vidjeti također dio 4.8. Prijavljene nuspojave odgovarale su onima koje su predviđene sigurnosnim profilima komponenata telmisartana i amlodipina.
The most common adverse reactions were: infusion-related reactions (67.2%), infections (63.0%), pyrexia (59.8%), headache (34.4%), febrile neutropenia (28%), peripheral oedema (25.9%), nausea
Najčešće nuspojave bile su: reakcije povezane s infuzijom (67,2%), infekcije (63,0%), pireksija (59,8%), glavobolja (34,4%), febrilna neutropenija (28%), periferni edem (25,9%), mučnina (24,3%),
The most common adverse reactions which led to treatment discontinuation in the lixisenatide group were nausea (3.1%) and vomiting (1.2%).
Najčešće nuspojave koje su dovele do prekida liječenja u skupini na liksisenatidu bile su mučnina (3,1%) i povraćanje (1,2%).
The most common adverse reactions with LEMTRADA (in ≥20% of patients) are rash, headache, pyrexia, and respiratory tract infections.
Najčešće nuspojave lijeka LEMTRADA (u ≥ 20% bolesnika) su osip, glavobolja, pireksija i infekcije dišnih puteva.
The most common and consistently reported treatment-related adverse reactions associated with Kineret were ISRs.
Najčešće i dosljedno prijavljene nuspojave povezane s liječenjem Kineretom bile su reakcije na mjestu primjene (ISR).
The most common cardiovascular histories included hypertension (81%), coronary artery bypass graft (CABG), percutaneous transluminal coronary angioplasty (PTCA) or stenting (51%), angina (63%), and history of myocardial infarction (41%) or arrhythmia (33%); other medical history included diabetes (32%) and COPD (5%).
Najčešće kardiovaskularne bolesti u anamnezi bile su hipertenzija (81%), aortokoronarno premoštenje (CABG), perkutana transluminalna koronarna angioplastika (PTCA) ili postavljeni stentovi (51%), angina pectoris (63%), te preboljeli infarkt miokarda (41%) ili aritmija (33%); ostale bolesti iz anamneze uključivale su dijabetes (32%) i KOBP (5%).
The most common cause of death as reported by the investigator was tuberculosis (9 patients).
Najčešći razlog smrti, prema prijavama ispitivača bila je tuberkuloza (9 bolesnika).
The most common emergent resistance mutations in Eviplera-treated patients were M184V/I and E138K in reverse transcriptase.
Najčešće mutacije povezane s rezistencijom koja se pojavila na liječenje u pacijenata liječenih lijekom Eviplera bile su MV184V/I i E138K u reverznoj transkriptazi.
The most common events occurring during infusion were headache, nausea and hypotension and within 24 hours of infusion were dizziness and hypotension.
Najčešći događaji koji su se javljali tijekom infuzije bili su glavobolja, mučnina i hipotenzija, a unutar 24 sata nakon infuzije omaglica i hipotenzija.
The most common foetal visceral malformations included persistent truncus arteriosus and ventricular septum defect.
Najčešće fetalne visceralne malformacije uključivale su perzistirajući truncus arterious i defekt ventrikularnog septuma.
The most common general side effect of Eliquis is bleeding which may be potentially life threatening and require immediate medical attention.
Najčešća nuspojava lijeka Eliquis je krvarenje, koje može ugroziti život i stoga iziskuje hitnu medicinsku pomoć.
The most common Grade 3-5 adverse reactions were neutropenia (10%), and anaemia, febrile neutropenia, thrombocytopenia, sepsis, upper respiratory tract infection, and urinary tract infection (all at 1%).
Najčešće nuspojave 3. – 5. stupnja bile su neutropenija (10%) i anemija, febrilna neutropenija, trombocitopenija, sepsa, infekcija gornjih dišnih putova i infekcija mokraćnog sustava (svaka po 1%).
The most common grade 3/4 adverse reactions (≥ 5%) were neutropenia, pneumonia, thrombocytopenia, and febrile neutropenia.
Najčešće nuspojave stupnja 3/4 (≥ 5%) bile su neutropenija, pneumonija, trombocitopenija i febrilna neutropenija.
The most common haemorrhagic adverse event reported was conjunctival haemorrhage (up to 24%).
Najučestaliji zabilježeni štetni hemoragijski događaj bilo je krvarenje konjunktive (do 24%).
The most common individual side effects, affecting more than 10% of patients, are diarrhoea, rash, pruritus (itching), fatigue (tiredness), nausea (feeling sick), vomiting, decreased appetite and abdominal pain (stomach ache).
Većina uobičajenih individualnih nuspojava, koje se pojavljuju u više od 10% bolesnika su proljev, osip, pruritus (svrbež), iscrpljenost (umor), mučnina (osjećaj slabosti), povraćanje, smanjeni apetit i abdominalna bol (bol u želucu).
The most common infusion related reactions were mild and include rigors, pyrexia, flushing, headache, nausea, dyspnea, tremor and pruritus.
Najčešće reakcije povezane s infuzijom bile su blage i uključivale su tresavicu, pireksiju, crvenilo uz osjećaj vrućine, glavobolju, mučninu, dispneju, tremor i svrbež.
The most common NCI- CTCAE v.3 Grade 3-4 ADR (≥10%) was neutropenia.
Najčešća nuspojava lijeka stupnja 3-4 prema verziji 3 NCI-CTCAE kriterija (≥10%) bila je neutropenija.
The most common NCI-CTCAE v.3 Grade 3-4 ADRs (> 10%) were neutropenia, febrile neutropenia and leucopenia, and the most common serious adverse events were febrile neutropenia, neutropenia and diarrhoea.
Najčešće nuspojave stupnja 3-4 prema verziji 3 NCI-CTCAE kriterija bile su neutropenija, febrilna neutropenija i leukopenija, a najčešći ozbiljni štetni događaji bili su febrilna neutropenija, neutropenija i proljev.
The most common NCI-CTCAE v.3 Grade 3-4 ADRs (≥10%) were neutropenia, febrile neutropenia and leucopenia.
Najčešće nuspojave lijeka stupnja 3-4 prema verziji 3 NCI-CTCAE kriterija (≥10%) bile su neutropenija, febrilna neutropenija i leukopenija.
The most common NCI-CTCAE v.3 Grade 3-4 ADRs (≥10%) were neutropenia, febrile neutropenia, anaemia, leucopenia and diarrhoea.
Najčešće nuspojave lijeka stupnja 3-4 prema verziji 3 NCI-CTCAE kriterija (≥10%) bile su neutropenija, febrilna neutropenija, anemija, leukopenija i proljev.
The most common of these infusion-related reactions included cutaneous reactions (rash, pruritus, urticaria), pyrexia, headache, hypertension and flushing.
Najčešće reakcije povezane s infuzijom uključivale su kožne reakcije (osip, pruritus, urtikariju), vrućicu, glavobolju, hipertenziju i navale crvenila.
The most common opportunistic infections in patients receiving CellCept (2 g or 3 g daily) with other immunosuppressants in controlled clinical trials of renal (2 g data), cardiac and hepatic transplant patients followed for at least 1 year were candida mucocutaneous, CMV viraemia/syndrome and Herpes simplex.
Najčešće oportunističke infekcije koje se pojavljuju kod bolesnika koji primaju CellCept (2 g ili 3 g dnevno) uz druge imunosupresive u kontroliranim kliničkim ispitivanjima bolesnika s presađenim bubregom (podaci o dozi od 2 g), srcem i jetrom, tijekom praćenja od barem godinu dana, bile su mukokutana kandidijaza, citomegalovirusna (CMV) viremija/sindrom i herpes simpleks.
The most common opportunistic infections in patients receiving mycophenolate mofetil (2°g or 3°g daily) with other immunosuppressants in controlled clinical trials of renal (2°g data), cardiac and hepatic transplant patients followed for at least 1°year were candida mucocutaneous, cytomegalovirus (CMV) viraemia/syndrome and Herpes simplex.
Najčešće oportunističke infekcije koje se pojavljuju kod bolesnika koji primaju mofetilmikofenolat (2 g ili 3 g dnevno) uz druge imunosupresive u kontroliranim kliničkim ispitivanjima bolesnika s presađenim bubregom (podaci o dozi od 2 g), srcem i jetrom, tijekom praćenja od barem godinu dana, bile su mukokutana kandidijaza, citomegalovirusna (CMV) viremija/sindrom i herpes simpleks.
The most common prior therapies included pemetrexed (38%), gemcitabine (25%), taxane (24%), and bevacizumab (14%); 22% of patients received prior maintenance therapy.
Najčešće prethodne terapije uključivale su pemetreksed (38%), gemcitabin (25%), taksan (24%) i bevacizumab (14%); 22% bolesnika prethodno je primalo terapiju održavanja.
The most common reactions occurring after vaccine administration were local reactions at injection site.
Najčešće reakcije koje su se javljale nakon cijepljenja bile su lokalne reakcije na mjestu primjene.
The most common reason for withdrawal from study in Kineret-treated patients was injection site reaction.
Najčešći razlog za povlačenje iz ispitivanja u bolesnika liječenih Kineretom bila je reakcija na mjestu primjene.
The most common reasons for discontinuation of therapy with MULTAQ were gastrointestinal disorders (3.2% of patients versus 1.8% in the placebo group).
Najčešći razlog prekida liječenja lijekom MULTAQ bili su gastrointestinalni poremećaji (3,2% liječenih bolesnika naspram 1,8% ispitanika u skupini koja je primala placebo).
The most common reported form of bleeding was minor (grade 1-2) epistaxis occurring in 27.7% of patients treated with the ZALTRAP/FOLFIRI regimen.
Najčešće prijavljen oblik krvarenja bila je blaga epistaksa (stupnja 1-2), koja se javila u 27,7% bolesnika liječenih protokolom ZALTRAP/FOLFIRI.
The most common reported grades 3-4 reactions (≥5% incidence) reported at least 2% greater incidence for the ZALTRAP/FOLFIRI regimen as compared to the placebo/FOLFIRI regimen in order of decreasing frequency, were neutropenia, diarrhoea, hypertension, leucopenia, stomatitis, fatigue, proteinuria, and asthenia (see Table 1).
Najčešće prijavljene reakcije stupnja 3-4 (incidencija ≥ 5%) za koje je prijavljena incidencija u skupini koja je primala protokol ZALTRAP/FOLFIRI bila najmanje 2% veća od one u skupini koja je primala protokol placebo/FOLFIRI, navedene prema učestalosti u padajućem nizu, bile su neutropenija, proljev, hipertenzija, leukopenija, stomatitis, umor, proteinurija i astenija (vidjeti Tablicu 1).
The most common reported reasons for discontinuation were cellulitis (0.4%, 4/976) and osteomyelitis (0.3%, 3/976).
Najčešće prijavljivani razlozi za prekid liječenja bili su celulitis (0,4%, 4/976) i osteomijelitis (0,3%, 3/976).
the most common serious ADRs (> 0.5% of patients) were haemorrhage, pyrexia, dyspnoea, musculoskeletal pain, thrombocytopenia, abdominal pain and vomiting. the most common adverse drug reactions (ADRs) (≥25%) with trastuzumab emtansine were nausea, fatigue, and headache.
najčešće ozbiljne nuspojave na lijek (> 0,5% bolesnika) bile su krvarenje, pireksija, dispneja, bol u mišićno-koštanom sustavu, trombocitopenija, bol u abdomenu i povraćanje. najčešće nuspojave (≥ 25%) trastuzumab emtanzina bile su mučnina, umor i glavobolja.